GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Onesource Specialty Pharma Ltd

Onesource Specialty Pharma: Q4 FY26 Revenue ₹4,282 million, EBITDA ₹919 million

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 13 May 2026, 01:46 PM IST  ·  BSE ID: 0a03e97b-d569-42e3-8ef5-49d295be0e86
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported significantly higher sales and profits this quarter compared to the last, while confirming its long-term financial targets.
🤖 AI Summary
  • Onesource Specialty Pharma reported Q4 FY26 consolidated revenues of ₹4,282 million, up 47% QoQ.
  • Q4 FY26 EBITDA expanded over 5x quarter-on-quarter to ₹919 million, reaching an EBITDA margin of 21%.
  • Adjusted PAT for Q4 FY26 was ₹390 million, moving from a loss to profit sequentially.
  • Full-year FY26 revenues were ₹14,216 million, a 2% decrease year-on-year.
  • Company reaffirmed FY28 guidance of ~$400 million organic revenue with ~40% EBITDA margin.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Q4 FY26 Revenues
₹4,282 million
Q3 FY26 Revenues
₹2,903 million
47%
Q4 FY26 EBITDA
₹919 million
Q3 FY26 EBITDA
₹173 million
5x+
Q4 FY26 EBITDA %
21%
1550bps
FY26 Revenues
₹14,216 million
(2%)
FY25 Revenues
₹14,449 million
FY26 EBITDA
₹3,042 million
(35%)
FY25 EBITDA
₹4,665 million
FY26 Adjusted PAT
₹739 million
(68%)
FY25 Adjusted PAT
₹2,314 million
🏢 How This Affects the Company
📈
Business Impact
The company's Q4 FY26 revenue growth of 47% QoQ, driven by India semaglutide launches and growth across service offerings, indicates an expansion of its commercialization momentum. New launches in US injectables and soft-gelatin businesses, alongside Canadian semaglutide approvals, support sustained growth into FY27.
💰
Financial Impact
Q4 FY26 EBITDA expanding over 5x QoQ to ₹919 million and Adjusted PAT reaching ₹390 million reflects improved operating leverage and profitability. However, full-year FY26 revenues decreased by 2% YoY to ₹14,216 million, and EBITDA declined by 35% YoY to ₹3,042 million, primarily due to delayed semaglutide approvals in Canada and an elevated cost base for its DDC facility ramp-up.
⚙️
Operational Impact
The company's successful semaglutide launches in India and recent approvals in Canada point to expanded product commercialization and market penetration. The ramp-up of the DDC facility contributed to an elevated cost base in FY26, indicating increased operational capacity for future growth.
⚠️
Risk Impact
The company acknowledged delayed semaglutide approvals in Canada impacted its FY26 performance. The reaffirmation of FY28 guidance provides a forward-looking operational target, but its achievement depends on timely regulatory approvals and sustained commercialization efforts.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company's financial performance influences its intrinsic value. Adjusted EPS for Q4 FY26 was ₹3.4, compared to (₹4.1) in Q3 FY26.
🔍
Management Signal
Management's reaffirmation of its FY28 guidance signals confidence in its long-term strategy and commercialization plans, despite a transitional FY26.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q1 FY27 results — evaluate sustained growth post semaglutide launches in India and Canada.
Updates on US injectables and soft-gelatin business launches — track expansion in these segments.
Progress on biologics pipeline — monitor for new approvals or expansion announcements.
MEDIUM RISK Full-year revenue and EBITDA declines indicate challenges; dependency on regulatory approvals for new product launches.
💡 Investor Takeaway
Onesource Specialty Pharma reported Q4 FY26 revenues of ₹4,282 million, up 47% QoQ, and EBITDA of ₹919 million, expanding over 5x QoQ. Full-year FY26 revenue decreased 2% YoY to ₹14,216 million, with EBITDA down 35% YoY to ₹3,042 million. The company reaffirmed FY28 guidance of ~$400 million in organic revenue with ~40% EBITDA margin.
⚖️ Strengths & Concerns

✅ Positives

  • Q4 FY26 revenues increased 47% QoQ to ₹4,282 million, driven by India semaglutide commercial launches and growth across all service offerings.
  • EBITDA for Q4 FY26 expanded over 5x QoQ to ₹919 million, with EBITDA margin improving to 21%, reflecting operating leverage on higher CSA revenues.

⚠️ Concerns

  • Full-year FY26 revenues decreased by 2% YoY to ₹14,216 million, impacted by a softer second half and delayed semaglutide approvals in Canada.
  • Full-year FY26 EBITDA declined 35% YoY to ₹3,042 million, attributed to a high MSA base in the prior year and an elevated cost base from the DDC facility ramp-up.
📅 Company Track Record
The previous filing on May 13, 2026, also highlighted Q4 FY26 revenue up 47% QoQ to ₹4,282 million and EBITDA expanded 5x+, consistent with the current press release details. This suggests a strong sequential recovery in the latest quarter following a challenging full fiscal year.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.